- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05745740
Une étude sur le RC48-ADC combiné au pyrotinib pour le traitement du NSCLC local avancé ou métastatique avec mutation HER2
Une étude ouverte, monocentrique, de phase Ib/II pour évaluer l'innocuité, l'efficacité et la pharmacocinétique du RC48-ADC combiné au pyrotinib dans le CPNPC local avancé ou métastatique avec mutation HER2
This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Na Su
- Numéro de téléphone: +8610-58075763
- E-mail: na.su@remegen.cn
Sauvegarde des contacts de l'étude
- Nom: Jianmin Fang, Ph.D
- Numéro de téléphone: +8610-58075763
- E-mail: jianminfang@hotmail.com
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200433
- Shanghai Pulmonary Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Voluntary agreement to provide written informed consent.
- Predicted survival ≥ 12 weeks.
- According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically removed, locally advanced or metastatic NSCLC.
- Is willing and able to provide an adequate archival tumor tissue sample
- Has relapsed from or is refractory to standard treatment and had received both platinum-based therapy and immunotherapy.
- Measurable lesion according to RECIST 1.1.
- Documented HER2 exon 20 insertion mutation.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- Adequate organ function.
- For female subjects: should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive (such as an intrauterine device, contraceptives, or condoms) during study treatment and within 6 months after the end of study, the blood pregnancy test within 7 days of study enrollment must be negative and must be non-lactating. Male subjects: Patients who should be surgically sterilized or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study.
- Willing and able to follow trial and follow-up procedures.
Exclusion Criteria:
- No known EGFR, ALK, ROS1, RET, NTRK, MET 14 or BRAF V600E mutation.
- Patient has had previous treatment with HER2-targeted therapy prior to study participation.
- History of major surgery within 4 weeks of planned start of trial treatment.
- Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive.
- Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
- NYHA Class III heart failure.
- Suffering from active infection requiring systemic treatment.
- Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD.
- Treated with systemic treatment (e.g. immunomodulators, corticosteroids or immunosuppressants) for the autoimmune disease within 2 years prior to the study treatment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: RC48-ADC + Pyrotinib
|
RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Autres noms:
Pyrotinib 400 mg by oral once a day. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
maximal tolerance dose (MTD) of RC48-ADC combined with Pyrotinib
Délai: DLT will be evaluated on 28 days of observation period
|
Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window. |
DLT will be evaluated on 28 days of observation period
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall response rate (ORR)
Délai: Up to approximately 3 years
|
The objective response rate will be mainly analyzed by investigators according to the RECIST 1.1 standard tumor evaluation. |
Up to approximately 3 years
|
|
Disease control rate (DCR)
Délai: Up to approximately 3 years
|
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study. |
Up to approximately 3 years
|
|
Duration of relief (DOR)
Délai: Up to approximately 3 years
|
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death. |
Up to approximately 3 years
|
|
Progression-free survival (PFS)
Délai: Up to approximately 3 years
|
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death. |
Up to approximately 3 years
|
|
Overall survival (OS)
Délai: Up to approximately 3 years
|
The objective response rate will be mainly analyzed by investigators according to the RECIST 1.1 standard tumor evaluation |
Up to approximately 3 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- RC48-C021
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .